Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK

Last updated:
2026-08-15
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 1/2 STUDY OF MIRDAMETINIB AND VINBLASTINE FOR NEWLY DIAGNOSED OR PREVIOUSLY UNTREATED PATIENTS WITH PEDIATRIC LOW-GRADE GLIOMA AND ACTIVATION OF THE MAPK PATHWAY

Intervention/treatment:
MIRDAMETINIB / VINBLASTINE
Medical condition:
GLIOMA
Protocol code:
MIRV
Control number:
297676
Status:
Recruiting
Approved:
June 04, 2025
Trial phase:
Phase 1, Phase 2
For more information:
ClinicalTrials.gov - NCT06666348
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
2 Years to 25 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Sébastien Perreault, M.D, FRCPC
Role
CONTACT
Phone:
514-345-4931
Extension 5019
Name
MIRV Study Team
Role
CONTACT
Sponsor
CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE

Locations

Alberta

Alberta Children's Hospital
Calgary, Alberta, T3B 6A8
Recruiting
Name
Lucie Lafay-Cousin, MD
Role
CONTACT
Phone:
(403) 955-7272
Stollery Children's Hospital
Edmonton, Alberta, T6G 2E1
Recruiting
Name
Liana Nobre, MD
Role
CONTACT
Phone:
(780) 248-1646

British Columbia

Childrens and Womens Health Centre of British Columbia - British Columbia Childrens Hospital
Vancouver, British Columbia, V6H 3V4
Recruiting
Name
Sylvia Cheng, MD
Role
CONTACT
Phone:
(604) 875-2406
Extension 52678

Manitoba

Cancer Care Manitoba
Winnipeg, Manitoba, R3E 0V9
Recruiting
Name
Issai Vanan, MD
Role
CONTACT
Phone:
204-787-4156
Extension 52678

Ontario

Children's Hospital, London Health Sciences Centre
London, Ontario, N6A5W9
Recruiting
Name
Chantel Cacciotti, MD
Role
CONTACT
Phone:
(519) 685-8500
Extension 52433
The Hospital for Sick Children
Toronto, Ontario, M5G 1E8
Recruiting
Name
Anthony Liu, MD
Role
CONTACT
Phone:
(416) 813-7654
Extension 5019
Name
Ashley Doka, CRPC
Role
CONTACT
Phone:
(416) 813-7654
Extension 427327

Quebec

CHU de Québec - Université Laval
Québec, Quebec, G1V 4G2
Recruiting
Name
Valérie Larouche, MD
Role
CONTACT
Phone:
(418) 525-4444
Extension 40121
CHU de Sherbrooke
Sherbrooke, Quebec, J1H 5N4
Recruiting
Name
Stéphanie Vairy, MD
Role
CONTACT
Phone:
819-346-1110
Extension 73068
CHU Sainte-Justine
Montreal, Quebec, H3T 1C5
Recruiting
Name
Sébastien Perreault, MD
Role
CONTACT
Phone:
514-345-4931
Extension 5019
Name
Marie Galopin, RN
Role
CONTACT
Phone:
514-345-4931
Extension 6326
Did you find what you were looking for?

Contacts and resources